2023
DOI: 10.31631/2073-3046-2023-22-3-70-77
|View full text |Cite
|
Sign up to set email alerts
|

New Russian Trivalent Hepatitis B Vaccine (Bubo<sup>®</sup>-Unigep): Clinical Study Results

V. N. Borisova,
R. Y. Maksvitis,
R. V. Ivanov
et al.

Abstract: Relevance. Currently, there is no registered vaccine against the hepatitis B virus (HBV) mutant G145R worldwide, which justifies the need to develop a new generation of vaccines due to large-scale immunization against hepatitis B and the accumulation of escape mutants of the virus.The aim of the study was a comparative assessment of the immunogenicity, reactogenicity and safety of Bubo®-Unigep (trivalent hepatitis B recombinant yeast vaccine) and the drug Hepatitis B recombinant yeast vaccine.Materials and met… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 11 publications
0
0
0
Order By: Relevance